Latest Growth Strategy News

Big River Industries reports a 3.3% revenue decline in 1H FY25 but shows signs of operational resilience and strategic progress amid challenging market conditions.

Baby Bunting has reported a robust first half for FY25, with net profit after tax rising 37% to $4.8 million and sales edging up 2.4%. The company’s strategic initiatives around margin improvement and store expansion underpin a stable outlook for the full year.

Baby Bunting has reported a robust first half of FY25 with a 37% rise in pro forma NPAT and solid sales growth, underpinned by strategic execution and margin expansion.

HUB24 has reported a robust first half FY25 with a 41% jump in underlying EBITDA and upgraded its FY26 platform funds under administration target, underscoring its accelerating market momentum.

SRG Global has reported a record first half for FY25, posting a 21% revenue increase and upgrading its full-year profit guidance, driven by strong cash flow and successful integration of the Diona acquisition.

Challenger Limited reported a robust first half of FY25 with a 12% rise in normalized NPAT and a 12% increase in its interim dividend, driven by strong annuity sales and strategic technology investments.

Challenger Limited reported a robust first half of FY25, delivering a 12% rise in normalised net profit after tax and record annuity sales, underpinned by strategic technology investments and longer tenor products.

Judo Capital Holdings Limited reported a robust 54% increase in statutory profit before tax for the half year ended December 2024, driven by strong SME loan growth and prudent cost management, despite a slight dip in net interest margin and statutory profit after tax.

QMines Limited has raised $6 million through a strongly supported placement, positioning the company to accelerate exploration and development at its Mt Chalmers and Develin Creek copper and gold projects.

Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Australian Bond Exchange Holdings has entered a strategic Liquidity Provision Agreement with ViewTrade Australia, aiming to broaden investor access to OTC securities globally through integrated technology and expanded market channels.